Glenmark Pharma Presentations & Investor Relations material

Glenmark is a leading global innovative pharmaceutical company committed to enriching lives worldwide. Our vision is to discover possibilities and make the lives of patients better across the globe by developing cures for unmet medical needs. We have a rich pipeline of innovative molecules in various phases of development which are targeted in the areas of oncology, respiratory and dermatology. Our molecules, in development, include Novel Biologics Entities and Novel Chemical Entities - all of which are first in class globally. In addition to novel monoclonal antibodies, Glenmark has developed its proprietary technology platform 'BEAT' for the production on Bi-Specific Antibodies which will provide next-generation targeted biologics for cancer therapy. (Read more on www.glenmarkpharma.com/BEAT) Our Generics business spans across multiple geographies with the US market being our largest. Our efforts to deliver affordable quality pharmaceuticals across the world consist of a rich pipeline of innovative molecules in various phases of development which are targeted in areas of oncology, respiratory and dermatology. Through our molecules, in development